H5N1 nasal powder vaccine

The H5N1 nasal powder vaccine is an experimental, needle-free vaccine candidate designed for pandemic preparedness against avian influenza. Developed primarily by researchers at the University of Groningen in collaboration with Intravacc, the vaccine utilizes a whole inactivated virus (WIV) platform. This approach incorporates the entire virion, including key surface antigens like hemagglutinin (H5) and neuraminidase (N1), as well as internal proteins, which may enhance cross-reactive T-cell immunity. The vaccine is formulated as a dry powder, often stabilized with excipients such as inulin, to allow for intranasal administration. This delivery route targets the nasal-associated lymphoid tissue (NALT) to elicit both local mucosal IgA and systemic IgG responses, potentially blocking viral entry at the primary site of infection. The dry powder formulation offers significant advantages in thermostability, potentially eliminating the need for cold-chain logistics and facilitating rapid distribution during an outbreak.

Other names

H5N1 dry powder vaccineH-5N1 dry powder vaccineH 5N1 dry powder vaccineIntranasal H5N1 whole inactivated virus vaccineGroningen H5N1 nasal powder vaccine